OcuMedic, Inc. United States

Replace eye drops from FREEDOM drug releasing clear contact lens corneal bandage. The device has a 7 day wear time consistent with the standard of care recall after; cataract, LASIK surgery & corneal abrasion & non infectious Uveitis. Doctor puts device on and takes it off eliminating patient compliance problems with quicker healing with drug constantly treating the target tissue. 10 granted patents with FTO legal opinion. 10 mono and combo ophthalmic Dougs tested. Completed in vivo safety study. Letter and meeting being set with the US FDA for phase 1-2 clinical in January 2021.
Company Size (Fulltime employees)
Year of foundation
2006
Please specify your partnering goal
Investment regulatory CFDA, manufacturing & distribution
Headquartner in China
Mr. Keith Ignotz
President & CEO 
Functionality

PhysioCue United States

PhysioCue is digital health and therapy device development company, has developed a non-invasive hypertension therapy device and a migraine and headache therapy device and migraine and headache pain monitoring mobile app. Using our device once daily for 5-minute treatments gradually elongated the reduced blood pressure. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with drugs. We have manufactured our devices and delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhysioCue devices can help people and save lives.

Company Size (Fulltime employees)
Year of foundation
2014
Headquartner in China
Medtech Category
Medtech Information 1
Thermal neurostimulation technology for a non-invasive hypertension therapy device
Slides Deck
(pdf, 6.11MB)
Simon Yi
LinkedIn logo President 
Functionality

Phyteau United States

Phyteau is developing an innovative, new class of therapeutics for diabetes, obesity, related conditions like NAFLD, NASH and prediabetes, and weight-loss. Unlike many drugs in the market today, our therapeutics are completely safe, and free of adverse side-effects.

Phyteau’s new incretin-based approach activates the body’s natural metabolic system
by triggering specialized enteroendocrine cells in the lining of the intestines to release
therapeutic levels of key hormones, including GLP-1, PYY and CCK. These boosted hormones:

1) signal insulin release,
2) reduce blood sugar levels and peaks, and HbA1c,
3) reduce appetite, food intake and weight, increase satiety,
4) slows gastric emptying and intestinal motility,
5) improve metabolism and fat thermogenesis,
6) reduce liver fat and fibrosis,
7) protect against many age-related functional declines and conditions, and
8) provide restorative and protective benefits to the cardiovascular and nervous systems and major organs

The result is safe and affordable first-line treatments that provide a powerful tool for blood sugar control, weight-loss and improving metabolism. Our technology, developed at Caltech, UCLA and Cedars Sinai Medical Center, has 3 patents awarded, 5 more pending, with more planned.

Phyteau’s deep technology platform and portfolio of agents allows us to address growing unmet global needs in a variety of markets. We have 3 pharmaceutical products in development as well as breakthrough medical and functional food products and other consumer health & nutrition products.

Year of foundation
2017
Headquartner in China
Assets Information 1
Phyteau's therapeutic platform represents a comprehensive range of gut hormone secretagogues. Our gut hormone secretagogues are powerful agonists for GCPR's on enteroedocrine cells in the intestines, causing the therapeutic release of metabolic gut hormones (including GLP-1, PYY and CCK).
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 294.95KB)
Bonn Macy
CEO 
Functionality

Product Creation Studio United States

PCS provides new product engineering and design services for medical device and Medtech companies. We have served enterprise and entrepreneurs for over two decades and our QMS is ISO13485:2016 certified.
Company Size (Fulltime employees)
Year of foundation
21
Please specify your partnering goal
Provide high-end medical device design capabilities to Chinese healthcare companies.
Headquartner in China
Target client type
Companies in need of custom medical devices, drug delivery solutions, diagnostics or research tools
Dr. Scott Thielman
CTO 
Functionality

QIAGEN United States

diagnostics
Website:
www.qiagen.com
Company Size (Fulltime employees)
Please specify your partnering goal
CDx partnership
Headquartner in China
Biotech/Pharma Category
Dr. Kai Zhang
PM 
Dr. Kai Zhang
PM 
Functionality

QiRun Biotech China

QiRun Biotech is focused on Parkinson's disease CDSS research and development. Currently PDCARE program has achieved cooperation With China pharmaceutical university and hospital's support.
Partnering Objectives
Headquartner in China
Yuqi Wang
Founder 

SAPA-DC United States

NGO
Website:
Www.sapadc.org
Headquartner in China
Biotech/Pharma Category
Vince Deng
President 

Shenzhen市松子生物科技有限公司 China

专注糖尿病和高尿酸血症
Partnering Objectives
Headquartner in China
位松 吴
CEO 

Sino-American Pharmaceutical Professionals Association United States

The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey, USA.  Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with eight chapters and more than 6,000 members.

SAPA’s members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production.

The organization’s large membership base and their superb scientific and technical abilities has allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries.

Website:
sapaweb.org
Company Size (Fulltime employees)
Year of foundation
1993
Please specify your partnering goal
Attending the conference and look for partners
Headquartner in China
Xiaodong Chen
President (2021-2022) 
Functionality